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Abstract
Background: EGFR overexpression has been described in many human tumours including gastric
cancer. In NSCLC patients somatic EGFR mutations, within the kinase domain of the protein, as
well as gene amplification were associated with a good clinical response to EGFR inhibitors. In
gastric tumours data concerning structural alterations of EGFR remains controversial. Given its
possible therapeutic relevance, we aimed to determine the frequency and type of structural
alterations of the EGFR gene in a series of primary gastric carcinomas.
Methods: Direct sequencing of the kinase domain of the EGFR gene was performed in a series of
77 primary gastric carcinomas. FISH analysis was performed in 30 cases. Association studies
between EGFR alterations and the clinical pathological features of the tumours were performed.
Results: Within the 77 primary gastric carcinomas we found two EGFR somatic mutations and
several EGFR polymorphisms in exon 20. Six different intronic sequence variants of EGFR were also
found. Four gastric carcinomas showed balanced polysomy or EGFR gene amplification. We verified
that gastric carcinoma with alterations of EGFR (somatic mutations or copy number variation)
showed a significant increase of tumour size (p  = 0.0094) in comparison to wild-type EGFR
carcinomas.
Conclusion: We demonstrate that EGFR structural alterations are rare in gastric carcinoma, but
whenever present, it leads to tumour growth. We considered that searching for EGFR alterations
in gastric cancer is likely to be clinically important in order to identify patients susceptible to
respond to tyrosine kinase inhibitors.
Background
Gastric cancer remains the second leading cause of cancer
death worldwide [1] a scenario that highlights the need
for more specific and efficient therapies. The exact mech-
anisms underlying gastric carcinogenesis are not yet fully
understood, but evidence points to an association with
pathways involved in developmental processes [2]. Key
molecules of these pathways are the receptor tyrosine
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kinases (RTKs), which are found to be aberrantly activated
or overexpressed in a variety of tumours and therefore rep-
resent promising targets for therapeutical intervention.
The members of the RTK superfamily of ERBB receptors
are glycoproteins that consist of an extracellular domain
where the binding of ligands takes place, a short lipophilic
transmembrane domain, and an intracellular domain car-
rying the tyrosine kinase activity [3,4]. They are expressed
in several tissues of epithelial, mesenchymal and neuronal
origin, where they play pivotal roles in development, pro-
liferation and differentiation. Deregulated expression of
ERBB molecules, namely ERBB2, has been implicated in
the development of numerous types of tumours, includ-
ing gastric tumours. In gastric carcinoma it has been
shown that ERBB2 overexpression is driven by gene
amplification and is associated to carcinomas with high
invasive potential [5]. ERBB1, better known as epidermal
growth factor receptor (EGFR), overexpression has been
described in many human tumours, including lung,
colon, breast, prostate, brain, head and neck, thyroid,
ovarian, bladder, kidney and also stomach cancer [6-11],
and has been correlated to advanced tumour stage and
poor clinical outcome. Very recently, we demonstrated
that EGFR activation is associated to loss of function of E-
cadherin, in vitro [12].
The mechanisms for oncogenic conversion of EGFR in
cancer include amplified copy number, structural rear-
rangements of the receptor, and activating mutations [13].
EGFR mutations cluster in the kinase domain of EGFR
(exons 18–21), and cause ligand-independent activation
of the receptor, representing possible targets for therapeu-
tical intervention. In this regard, somatic EGFR mutations
as well as gene amplification in patients with non-small
cell lung cancer (NSCLC) highly correlate with the clinical
response to tyrosine kinase inhibitors [14,15].
In gastric tumours, data concerning structural alterations
of EGFR remains controversial. Given its possible thera-
peutic relevance, in the present study we aimed to clarify
the relevance of EGFR structural alterations in gastric car-
cinogenesis by analyzing a series of primary gastric carci-
nomas for copy number and mutations in the tyrosine
kinase domain (exons 18–21) of the EGFR gene.
Methods
Case selection and histopathological classification of the 
tumours
Representative blocks of 77 formalin-fixed, paraffin
embedded human gastric primary tumours were retrieved
from the Department of Pathology of the Hospital S. João,
after informed consent of the patients. Patients were
informed that tumour material would be used for research
purposes only. None of the patients included in the
present series had a family history of gastric cancer. H&E-
stained sections were used to categorize tumours accord-
ing to the classifications of Lauren and Ming. Penetration
of the gastric wall and the presence and localization of
lymph node metastases were recorded for all patients
using standard criteria for pathological staging. Orcein-
stained sections were used for the detection of vascular
invasion.
EGFR Mutation Screening
Genomic DNA was extracted from 10 μm section after
microdissection of the tumour areas to ensure a purity of
at least 70% of neoplastic cells. DNA extraction was per-
formed using the Genomic DNA Purification Kit (Gentra
System) according to the manufacturer's protocol. Exon-
specific primers were designed and DNA was subjected to
PCR amplification of exons 18, 19, 20 and 21. The four
EGFR exons code for the tyrosine kinase domain of EGFR.
Primer sequences are shown in Table 1.
PCR products were run on a 2% agarose gel and PCR
amplified bands were extracted from the gel with the Gel
Band Purification Kit (GE Healthcare). Samples were then
purified and sequenced using the ABI Prism dGTP BigDye
Terminator Ready Reaction Kit (Perkin Elmer, Foster City,
CA) following manufacture's instruction and an ABI
Prism 3100 Genetic Analyser (Perkin Elmer, Foster City,
CA). The results were analysed using 3100 data collection
software. Sequencing was performed in both strands. In
cases with suspected mutations PCR amplification was
repeated and the sample was re-sequenced to rule out PCR
artefacts.
EGFR Copy Number Variation Screening
The paraffin blocks were sectioned at 5 μm and tissue sec-
tions were dried at 60°C for 30 minutes. The slides were
deparaffinised and washed followed by a pre-treatment
and a digestion step using pepsin and finally dehydrated.
The LSI EGFR Dual Color Probe-Hyb Set (VYSIS®), opti-
mized to detect the band region 7p12 in spectrum orange
and the centromere of chromosome 7 (7p11.1-q11.1,
Table 1: Primers used for PCR amplification of the EGFR kinase 
domain
Exon Primer Sequence PCR 
product 
size (bp)
Exon 18 Forward TGGGCCATGTCTGGCACTGC 283
Reverse ACAGCTTGCAAGGACTCTGG
Exon 19 Forward TCACTGGGCAGCATGTGGCA 241
Reverse CAGCTGCCAGACATGAGAAA
Exon 20 Forward CCTTCTGGCCACCATGCGAA 295
Reverse CGCATGTGAGGATCCTGGCT
Exon 21 Forward ATTCGGATGCAGAGCTTCTT 265
Reverse CCTGGTGTCAGGAAAATGCTBMC Cancer 2008, 8:10 http://www.biomedcentral.com/1471-2407/8/10
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D7Z1 locus) in spectrum green, both in interphase nuclei
and on metaphase chromosomes, was used. Five μl of the
probe were applied to each slide. The denaturation was
performed at 80°C for 8 minutes followed by hybridiza-
tion on a humid chamber at 37°C for 16 hours. After
hybridization, slides were washed and incubated with 4'-
6-Diamidino-2-phenylindole (DAPI) for nuclear staining.
For evaluation, sixty to 100 intact interphase nuclei were
analysed by two independent observers in order to score
the signals for the chromosome 7 centromere and the
EGFR gene. Surrounding lymphocytes and normal
mucosa were used as internal quality control for the
assays. At least two or three representative areas of the
neoplastic cells were selected, under a 100×/200× ampli-
fication field, to count the nuclei signals. After an over-
view under a 400× amplification, the signals were then
counted using immersion oil (1000×).
Statistical analysis
Association studies between EGFR alterations and the
clinicopathological features of the cases were performed
only in 30 cases (tumours analysed for EGFR mutations
and EGFR copy number variation). Statistical analyses
were assessed by the x2 test or Student's t test. A p value of
<0.05 was considered statistically significant.
Results
EGFR Mutation Screening
From the 77 gastric carcinomas analysed, EGFR mutations
in exons 18–21 were detected in 2.6% (2/77) of the cases
(Fig. 1A). One mutation belonged to exon 20 and was a
missense mutation (2300 C>T) leading to the substitution
of the Alanine 767 for a Valine. The second mutation
affected exon 21 and was a missense mutation (2524
A>G) leading to the substituition of the Asparagine 842
for an Aspartic acid. None of the mutations were previ-
ously described. No sequence alterations were found in
exons 18 and 19.
Several EGFR polymorphisms were found in exon 20
(Table 2). The polymorphism 2361G>A Gln787Gln, pre-
viously described by Mu et al [16], was present in 55.8%
(43/77) of the cases, and in nine of the 43 cases in a
homozygous state. We screened 50 normal controls and
the 2361G>A Gln787Gln was present in 82% of the con-
trols (41/50). Two other EGFR silent mutations (the 2301
C>T Ala767Ala and the 2415 C>T His805His) were found
in exon 20, none of them previously described. Both alter-
ations were found in a single case and were absent in nor-
mal controls.
We found six different sequence variants localized in
intronic regions of EGFR, two of them previously
described in Ensembl [17].
EGFR Copy Number Variation Screening
The analysis of EGFR copy number, as assessed by fluores-
cence in situ hybridization (FISH), was only possible in
30 of the 77 cases analysed for EGFR mutations. All EGFR
signals were compared to signals for centromeric probes
for chromosome 7. More than 2.0 EGFR copies per cell
(balanced polysomy or gene amplification) were detected
in 13.3% (4/30) of the cases. Of the four cases showing
more than 2 copies of EGFR per chromosome 7, three had
increased copy number due to polysomy and one had
gene amplification, a diffuse gastric carcinoma, exhibiting
Structural alterations in EGFR Figure 1
Structural alterations in EGFR. (A) Direct sequencing showing one of the mutations found in the kinase domain of EGFR – 
missense mutation (2300 C>T) in exon 20, leading to the substitution of the Alanine 767 for a Valine. (B) Diffuse gastric carci-
noma with EGFR increased copy number caused by chromosome 7 polysomy. (C) Neoplastic cells exhibiting gene amplification 
with the formation of clusters with numerous signals for EGFR.BMC Cancer 2008, 8:10 http://www.biomedcentral.com/1471-2407/8/10
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the formation of clusters with numerous signals for EGFR
(Fig. 1B, C).
EGFR structural alterations and clinicopathologic 
parameters of the patients and tumours
Table 3 shows the statistical associations between EGFR
alterations and the clinicopathologic characteristics of the
patients and tumours. When comparing gastric carcinoma
harbouring EGFR alterations with carcinomas with nor-
mal EGFR status or copy number, we observed a signifi-
cant association between EGFR structural alterations and
increased tumour size. (p = 0.0094). No significant associ-
ations were found between EGFR alterations and other
clinicopathologic parameters of the patients and tumours,
Table 3: Association of EGFR gene alterations with clinicopathological parameters
Clinicopathological parameters EGFR status
Amplification/mutation (n = 6) Normal (n = 24) Total (n = 30) p value
Sex (F/M) 1/5 10/14 11/19 0.2557
Age (SD) 62.3 ± 14,1 56.3 ± 16.8 57.5 ± 16.2 0.4271
Tumour localization 0.8548
Proximal 3 11 14
Distal 3 13 16
Size (SD) 11.6 ± 9.8 5.8 ± 2.0 6.9 ± 5.0 *0.0094
Lauren's classification 0.1261
Intestinal 1 12 13
Diffuse 5 9 14
Atypical 0 3 3
Wall penetration 0.4642
Early (T1) 0 2 2
Advanced (T2-T4) 6 22 28
Vascular Invasion 0.7125
Absent (N0) 3 14 17
Present (N = 1) 3 10 13
Lymph node metastasis 0.1921
Absent 1 11 12
Present 5 13 18
Staging 0.3845
I1 7 8
II 0 5 5
III 5 11 16
IV 0 1 1
Table 2: Sequence alterations found by direct sequencing
Alteration Type Frequency References
Exon 18
2184+19 G>A Intronic variant 2/77 Ensembl
SNP rs17337107 (dbSNP126) [17]
Exon 19
2185-9 C>G Intronic variant 1/77 Not yet described
2283+11 G>A Intronic variant 1/77 Not yet described
2283+47 G>A Intronic variant 1/77 Not yet described
2283+49 C>T Intronic variant 1/77 Not yet described
Exon 20
2284-60 C>T Intronic variant 2/77 Ensembl
SNP rs10241451 (dbSNP126) [17]
2300 C>T Missense Ala 767 Val 1/77 Not yet described
2301 C>T Silent Ala 767 Ala 1/77 Not yet described
2361G>A Silent Gln 787 Gln 43/77 [16]
2415 C>T Silent His 805 His 1/77 Not yet described
Exon 21
2524 A>G Missense Asn 842 Asp 1/77 Not yet describedBMC Cancer 2008, 8:10 http://www.biomedcentral.com/1471-2407/8/10
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namely gender and age of the patients, tumour localiza-
tion, histological type, wall penetration, the presence of
lymph node metastasis, vascular invasion and tumour
staging of the tumour.
Discussion
EGFR gene is located on chromosome 7p12 and codes for
a 170-KDa receptor, present in the membrane of cells as
an inactive monomers. Upon ligand binding to the extra-
cellular domain, the receptor undergoes conformational
changes, dimerises and becomes autophosphorylated in
key tyrosine residues in the intracellular tyrosine kinase
(TK) domain. This leads to the activation of downstream
pathways which control cell survival, inhibition of apop-
tosis and proliferation [18].
Much attention has been drawn to the oncogenic effect of
EGFR and most of all to success of EGFR target therapies,
which are well established for non small cell lung carcino-
mas. The role of EGFR in gastric cancer is very controver-
sial. Some authors reported that EGFR is highly expressed
in gastric cancer, suggesting its suitability as a target for
receptor tyrosine kinase inhibitors [19,20]. Conversely,
Takehana and colleagues reported that overexpression of
epidermal growth factor receptor is a rare event in gastric
carcinoma [21] and occurs predominantly due to EGFR
gene amplification, confirming results from previous
studies [22-24]. EGFR mutations in primary gastric carci-
noma or gastric cancer cell lines were never reported [25-
27]; nevertheless we recently showed that hereditary dif-
fuse gastric cancer associated E-cadherin germline mis-
sense mutations lead to increased EGFR activity.
On this basis, we considered that searching for EGFR alter-
ations in gastric cancer might have been important to
identify therapy susceptible cases.
Here we report the presence of EGFR  increased copy
number in 13.3% of the 30 cases in which FISH analysis
was possible. Of the four cases with increased copy
number, just one presented gene amplification, whereas
the remaining 3 cases showed polysomy of chromosome
7. These results match previous reports investigating the
EGFR copy number in gastric cancer [22-24]. The muta-
tional analysis of the kinase domain of EGFR revealed the
presence of mutations in 2.6% of 77 gastric carcinomas.
The identified mutations were of the missense type and
were present in exons 20 and 21 of the EGFR gene. None
of the identified mutations had been previously described
and their functional significance is not yet assessed. How-
ever, due to their localization in the kinase domain of
EGFR, it is tempting to speculate that they affect the activ-
ity of the receptor and therefore patients harbouring these
EGFR mutations may benefit from tyrosine kinase inhibi-
tors as therapeutic approach.
Besides these mutations found, other sequence alterations
were identified, all clustering in exon 20. The EGFR poly-
morphism 2361 G>A (previously described in Ensembl)
occurs in a high percentage of cases and in normal con-
trols. In contrast, the other two not yet described silent
variants in exon 20 (2301 C>T, 2415 C>T) were absent in
normal controls. In addition to these EGFR sequence var-
iants in coding regions, we have also identified variations
in the intronic sequence flanking exons 18, 19 and 20, but
their functional effect remains unclear.
The correlation of the clinical parameters for the cases for
which both mutation and FISH analysis was possible,
showed a significant association between EGFR altera-
tions and tumour size. Interestingly, all cases with altera-
tions in EGFR (amplification/mutation) were carcinomas
already invading the basal membrane and spreading into
the gastric wall (T2-T4), suggesting that alterations of this
gene may confer an invasive behaviour to neoplastic cells.
However, this hypothesis needs to be clarified by further
studies, since we did not verify a statistically significant
correlation between EGFR alterations and invasion in the
gastric wall (p = 0.4642), as we have just analised a very
low number of early gastric carcinomas (n = 2) in our
series. Both results are in agreement with the reports of
Hirono et al., 1995 [23] and Tsugawa et al., 1998 [24], sug-
gesting that EGFR is involved in tumour growth and acti-
vating alterations may be a late event involved in tumour
progression.
Although no other statistically significant association was
found, it is interesting to notice that EGFR alterations
occur mainly in carcinomas of the diffuse type. The pres-
ence of EGFR alterations in diffuse carcinomas is in con-
trast to what previously observed for other members of
the ERBB receptor family in gastric cancer. In gastric carci-
noma ERBB2 amplification was detected preferentially in
intestinal carcinomas of the stomach [5].
Conclusion
In conclusion, in this study we demonstrated that EGFR
activating alterations are not a frequent event in gastric
carcinogenesis. Alterations preferentially appear in gastric
carcinomas of the diffuse subtype and are associated to
tumour size. Despite the low frequency of EGFR altera-
tions, our results also indicate that there is a restricted
group of selected gastric patients that might benefit from
non conventional therapies, including pharmacological
inhibitors of the EGFR receptor.
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